Navigation Links
Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients
Date:1/8/2012

MELBOURNE, Australia, Jan. 8, 2012 /PRNewswire/ -- Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre.

The Phase 1 study will examine the safety and tolerability of escalating doses of VGX-100 in patients with advanced solid tumours who have no other standard treatment options both as a monotherapy and also when used in combination with other anti-angiogenic agents.  Results from the trial are expected to be available in the second half of 2012.

"We are extremely proud to have completed the translation of VGX-100 from early discovery to the clinical development stage. We are committed to improving outcomes for patients suffering from cancer, and believe that VGX-100, especially when combined with existing therapies could make a significant difference. Commencing clinical trials with VGX-100 is an extremely important achievement for Circadian and a major step in our goal to develop VGX-100 as a new therapeutic agent in the fight against cancer," said Robert Klupacs, CEO of Circadian Technologies Limited.

VGX-100 is a human antibody that acts against the human VEGF-C protein.  Treatment for cancers, particularly glioblastoma and metastatic colorectal cancers, are the first target indications for VGX-100. Additionally, Circadian is developing VGX-100 for a number of other cancer indications, as well as an agent to treat front-of the-eye diseases.

Studies in animal model studies across a wide range of tumour types have shown that when combined with Avastin® and/or chemotherapy, VGX-100 can significantly reduce tumour growth and tumour spread as well as significantly improve tumour inhibition over and above that of Avastin® and/or chemotherapy alone. Recent studies have also implicated VEGF-C as a key mediator of disease
'/>"/>

SOURCE Circadian Technologies Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Circadiance Launches Revolutionary New CPAP Tube
2. Circadian Receives FDA IND Approval to Begin Clinical Trials With VGX-100 for the Treatment of Cancer Patients With Solid Tumors
3. Circadian Files IND With FDA for VGX-100 for the Treatment of Cancer Patients With Solid Tumors
4. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
5. Ikaria® Commences Global Registration Trial for Bioabsorbable Cardiac Matrix
6. Coronado Biosciences Commences Public Trading on the OTC Bulletin Board
7. Hotspur Technologies Commences US Launch at Veith/AIM Conference in New York City
8. CryoLife Commences Tender Offer for All Outstanding Shares of Cardiogenesis Corporation
9. Unilife Commences Initial Production of Unifill Prefilled Syringe
10. Quest Diagnostics Commences Tender Offer for Acquisition of Celera
11. Milestone Scientific Inc. Commences Trading on the OTC Pink
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015 Acsis Inc., the market ... solutions, announced it will be hosting a free webinar ... event, "How to Boost Manufacturing Efficiency and Optimize Supply ... at 2:00 PM EDT.  Presenters ... John Gordon , Chief Information Officer for Roosevelt ...
(Date:3/4/2015)... AUSTIN, Texas , March 4, 2015 /PRNewswire/ ... Phase II pilot study in patients with moderate ... JAMA Dermatology. The open-label Phase II trial evaluated ... Human™ monoclonal antibody that targets interleukin-1 alpha (IL-1a). ... and inflammatory cells present in skin lesions. The ...
(Date:3/4/2015)... March 4, 2015   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of innovative ... will present at the Barclays Global Healthcare Conference ... Loews Miami Beach Hotel in Miami ... , M.D., President and Chief Executive Officer of Aratana ...
Breaking Medicine Technology:XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2
...  1, 2011 CardioGenics Holdings Inc. (OTC Bulletin ... CardioGenics and Merck Chimie SAS continue the commercialization ... CardioGenics that while it is refining its encapsulation ... a batch of magnetic beads coated with CardioGenics, ...
... Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: ... on developing topically administered products using its proprietary transdermal ... exploring strategic alternatives aimed at enhancing shareholder value with ... Advisors, a division of KEMA Partners.  The goal ...
Cached Medicine Technology:CardioGenics to Continue Commercialization of its Magnetic Beads with Merck Chimie SAS 2CardioGenics to Continue Commercialization of its Magnetic Beads with Merck Chimie SAS 3Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 2Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 3
(Date:3/4/2015)... Vancouver, BC (PRWEB) March 04, 2015 ... Center, has recently received two awards in the ... Choice Awards on February 27, 2015. The company ... and second place in the “Best Registered Massage ... largest distributed community newspapers in Canada, The Vancouver ...
(Date:3/4/2015)... 2015 State officials have awarded $82,500 ... of Public Health at Georgia State University, to support ... by Georgia’s Division of Family and Children Services (DFCS) ... Call Center. , The 1-800-CHILDREN Helpline is a ... and referral services that promote the wellbeing of children ...
(Date:3/4/2015)... 2015 The popular all-natural supplement brand, ... L-Style Revolution™ Program. The customized program provides a tailored ... all health and fitness levels to follow and achieve ... traditional methods. , “We’re really proud to announce our ... on award winning techniques to help people according to ...
(Date:3/4/2015)... Columbus is no stranger to drug addiction. The bustling ... and suffers from the potential threat of Kratom. In a ... revealed that Kratom is a “drug of concern.” Although Kratom ... herb from Southeast Asia acts as a stimulant in low ... foments symptoms similar to heroin withdrawal, and includes tremors, irritation, ...
(Date:3/4/2015)... March 04, 2015 According to a ... of people in the U.S. suffer from gastroesophageal reflux ... are commonly prescribed to control acid production, but these ... can overly correct the problem and lead to other ... GERD occurs when the lower esophageal sphincter does not ...
Breaking Medicine News(10 mins):Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2Health News:Columbus, OH Combats the Sale of Kratom as a Drug, Harbor Village Detox Stresses Caution 2Health News:New and Proven Acid Reflux Treatments Offer Relief to Millions of Americans 2Health News:New and Proven Acid Reflux Treatments Offer Relief to Millions of Americans 3
... Mozes HealthDay Reporter , THURSDAY, July 7 (HealthDay ... overstretched anterior cruciate ligament (ACL) appear to face a higher ... cartilage, new Norwegian research indicates. Such holes can result ... injury, and these lesions can raise the chances of developing ...
... research and treatment of pediatric leukemia at St. Jude Children,s ... Henry M. Stratton Medal from the American Society of Hematology ... the fight against this blood cancer during the past three ... co-founder of Grune and Stratton, the medical publishing house that ...
... function of sex is to promote genetic diversity. But ... Molecular Medicine and Genetics, says that,s not the case. ... associate professor at Carleton University in Canada, propose that ... the primary function of sex is not about promoting ...
... target that could stop the growth of glioblastoma, a deadly ... the journal Cell , a Cell Press publication, a ... that allows them to grow and seed tumors. Importantly, normal ... share that same dependency. "When thinking about therapeutics [targeting ...
... Bradley Mullens , a professor of entomology at the ... the prestigious Entomological Society of America (ESA), the ... needs of entomologists and people in related disciplines. ... elected to this honor. They will be recognized at the ...
... HealthDay Reporter , WEDNESDAY, July 6 (HealthDay News) -- For ... silver bullet to alleviate the condition has yet to be ... spinal manipulative therapy (SMT) to other treatments such as medication, ... SMT appears to be no better or worse than other ...
Cached Medicine News:Health News:Men Seem More Likely Than Women to Develop Hole in Knee Cartilage 2Health News:Men Seem More Likely Than Women to Develop Hole in Knee Cartilage 3Health News:Ching-Hon Pui, M.D., honored by the American Society of Hematology for work in childhood cancer 2Health News:Wayne State University researcher argues that sex reduces genetic variation 2Health News:To combat deadly brain cancer, target the stem cells 2Health News:UC Riverside faculty member elected fellow of Entomological Society of America 2Health News:Study Questions Chiropractic's Impact on Back Pain 2Health News:Study Questions Chiropractic's Impact on Back Pain 3
... Olympus TrueView II telescopes are based on ... unique wide field of view allows a tremendous ... view supports easy navigation in the joint with ... new quick lock mechanism for tight and secure ...
... WASCA Analyzer provides youwith new, exciting possibilities ... the WASCA Analyzeranalyzes the optical properties of ... the retina. In addition to refractive values, ... aberrations which were largely ignored in the ...
... Flow Unit is a flexible, total solution. , ... operating theaters since 1983. A major part of ... extensive experience from all the different areas of ... , ,Kojair Tech Oy is a comprehensive supplier. ...
The Universal Knee Positioner(s)™ reduces surgeon fatigue while assisting in the stabilization of a patient's leg during surgury....
Medicine Products: